Experimental drug tarlatamab targets tough lung cancer
NCT ID NCT03319940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new drug, tarlatamab, in 269 people with small cell lung cancer that has worsened after standard treatment. Tarlatamab is designed to help the body's immune cells find and attack cancer cells. The main goals are to check the drug's safety, find the right dose, and see how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tarlatamab (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for people with small cell lung cancer that has come back after standard therapy.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if tarlatamab will work. Side effects, including cytokine release syndrome, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biokinetica SA
Józefów, 05-410, Poland
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1011, Switzerland
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Christie Hospital
Manchester, M20 4BX, United Kingdom
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Europejskie Centrum Zdrowia Otwock Szpital imienia Fryderyka Chopina
Otwock, 05-400, Poland
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Gustave Roussy
Villejuif, 94805, France
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
John Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
-
Kantonsspital St Gallen
Sankt Gallen, 9007, Switzerland
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
Taoyuan, 33305, Taiwan
-
Maastricht Universitair Medisch Centrum
Maastricht, 6229 HX, Netherlands
-
Medizinische Universitaet Graz
Graz, 8036, Austria
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic
Columbus, Ohio, 43210, United States
-
Tri-Service General Hospital
Taipei, 11490, Taiwan
-
Universitaetsklinikum Wuerzburg
Würzburg, 97078, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Pittsburgh Medical Center Cancer Pavillion
Pittsburgh, Pennsylvania, 15232, United States
-
Wakayama Medical University Hospital
Wakayama, Wakayama, 641-8510, Japan
-
Washington University
St Louis, Missouri, 63110-1093, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06510, United States